Synthesis of New Benzoxazinone Derivatives as Neuropeptide Y5 Antagonists for the Treatment of Obesity
作者:Antoni Torrens、Josep Mas、Adriana Port、José Aurelio Castrillo、Olga Sanfeliu、Xavier Guitart、Alberto Dordal、Gonzalo Romero、M Angeles Fisas、Elisabeth Sánchez、Enrique Hernández、Pilar Pérez、Raquel Pérez、Helmut Buschmann
DOI:10.1021/jm049599u
日期:2005.3.1
NPY Y5 receptor and showing functional antagonism in the forskolin-induced cyclic AMP test. Prelimminary studies in order to understand the structure-activity relationship were undertaken. Selected compounds were further evaluated for in vivo efficacy, affording the lead compound 2-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)piperidin-1-yl]-N-(9-oxo-9H-fluo ren-3-yl)acetamide 5p, which displayed
我们针对神经肽Y5(NPY Y5)受体的内部化学物质的筛选可以将苯并恶嗪衍生物5f鉴定为具有中等亲和力的命中分子(IC(50)= 300 nM)。为了提高体外效能,已经合成了一系列2-苯并恶嗪酮衍生物,并测试了其NPY Y5活性。发现大多数化合物是有效的和选择性的NPY Y5拮抗剂,对NPY Y5受体具有纳摩尔结合亲和力,并且在毛喉素诱导的环AMP测试中显示出功能拮抗作用。为了理解结构-活性关系进行了初步研究。进一步评估所选化合物的体内功效,得到前导化合物2- [4-(8-甲基-2-氧代-4H-苯并[d] [1,3]恶嗪-1-基)哌啶-1-基] -N-(9-氧代-9H-氟烯-3-基)乙酰胺5p,